UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

___________________

FORM 8-K

___________________

CURRENT REPORT

Pursuant to Section 13 or 15(d) ~~of the~~

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 1720, 2025

___________________

Predictive Oncology Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-36790		33-1007393
(State or other jurisdiction of incorporation or organization)		(Commission File Number)		(I.R.S. Employer Identification No.)

___________________

Delaware	001-36790	33-1007393
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

91 43rd Street, Suite 110

Pittsburgh, PAPennsylvania 15201

(Address of ~~principal~~Principal ~~executive~~Executive ~~offices~~Offices) (Zip Code)

(412) 432-1500

(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

___________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	~~Trading~~Name ~~Symbol(s)~~of each exchange on which registered	~~Name of each exchange on which registered~~
Common stock, par value $0.01 per share		POAI	NASDAQ Capital Market
Common stock, $0.01 par value	POAI	NASDAQ Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 78.01 ~~Regulation FD Disclosure~~. Other Events.

As previously reported, on November 20, 2024, Predictive Oncology Inc. (the “Company”) ~~has~~received ~~scheduled~~ a ~~conference~~letter ~~call~~from ~~and~~The ~~webcast~~Nasdaq atStock ~~9:00~~Market ~~a.m.~~LLC ~~Eastern~~(“Nasdaq”) ~~Time~~notifying ~~on November 17, 2025, to discuss~~ the Company~~’s financial~~ ~~results~~that ~~for~~it ~~the~~was ~~third~~not ~~quarter~~in ~~ended~~compliance ~~September~~with ~~30,~~the ~~2025~~minimum ~~and~~stockholders’ ~~provide~~equity anrequirement ~~update~~for oncontinued ~~its~~listing ~~digital asset strategy. A presentation will be made available~~ on ~~the~~The ~~Company’s~~Nasdaq ~~investor~~Capital ~~relations~~Market ~~page.~~as Aset ~~copy~~forth ofin ~~the~~Nasdaq ~~presentation~~Listing isRule ~~furnished as Exhibit 99.~~5550(b)(1 ~~to this~~) ~~Current~~(the ~~Report~~“Stockholders’ onEquity ~~Form 8-K and incorporated herein by reference~~Requirement”).

~~The~~As ~~information~~also ~~included~~previously inreported, ~~this Item~~on October 7~~.01~~, ~~including Exhibit 99.1 hereto~~2025, ~~shall not be deemed “filed” for~~ the ~~purposes~~Company ofclosed ~~Section~~two 18private ofinvestment ~~the~~in ~~Securities~~public ~~Exchange Act~~equity ~~of 1934, as amended~~ (~~the~~ “~~Exchange Act~~PIPE”), ortransactions ~~otherwise~~and ~~subject~~received toan ~~the~~aggregate ~~liabilities~~ of ~~that~~approximately ~~section~~$343.5 million, ~~nor~~including ~~shall~~approximately it$50.8 bemillion ~~deemed incorporated~~in bycash ~~reference~~and ~~into~~approximately ~~any~~$292.7 ~~filing~~million ~~made~~in bynotional ~~the~~value ~~Company~~of ~~under~~in-kind ~~the~~contributions ~~Exchange Act or Securities Act~~ of ~~1933,~~certain ascrypto ~~amended~~assets, ~~except~~representing ~~as shall~~a bediscounted ~~expressly~~value ~~set~~of ~~forth~~approximately by$173.3 ~~specific reference in such a filing~~million.

~~Item~~As 9of the date of this Current Report on Form 8-K, the Company believes it has regained compliance with the Stockholders’ Equity Requirement, as its stockholders’ equity is in excess of $2.015 ~~Financial~~million ~~Statements~~following ~~and~~the ~~Exhibits~~closing of the PIPE transactions.

~~(d) Exhibits~~SIGNATURE

Exhibit No.		Description
99.1		Presentation dated November 17, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SIGNATURE

		Predictive Oncology Inc.


Date: November 20, 2025		By:   /s/ Josh Blacher
		Josh Blacher
		Chief Financial Officer

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Predictive Oncology Inc.
Date: November 17, 2025	By:	/s/ Josh Blacher
		Josh Blacher
		Chief Financial Officer

Filing Compare · Axe Compute Inc.